J Korean Cancer Assoc.  1998 Feb;30(1):169-177.

Treatment Result of Pediatric Osteosarcoma with Intraarterial Cisplatin

Affiliations
  • 1Department of Pediatrics, National University College of Medicine, Seoul, Korea.
  • 2Department of Radiology, National University College of Medicine, Seoul, Korea.
  • 3Department of Orthopedics, National University College of Medicine, Seoul, Korea.

Abstract

PURPOSE
This study was performed to determine the outcome after treatment of osteosarcoma with intraarterial cisplatin as a preoperative chematherapy regimen.
MATERIALS AND METHODS
Twenty five patients with extremity osteosarcoma were treated with intraarterial cisplatin at Seoul National University Children's Hospital from January 1987 to April 1996. The dose of cisplatin was 130 mg/m2 and three to six courses were repeated two- to three-week intervals, Systemic doxorubicin was added to six of these patients. This was followed by surgical resection(limb salvage or amputation) and postoperative adjuvant chemotherapy.
RESULTS
Limb-salvage was possible in twenty of these twenty five patients. Pulmonary metastasis was present in five patients at diagnosis and developed later in three patients. In six patients treated with systemic doxorubicin, pulmonary metastasis was absent at diagnosis and during follow-up period. Local recurrence after limb salvage was occurred in one patient and treated with amputation and systemic chemotherapy. Seven patients died from pulmonary metastssis and one from unknown cause. The follow-up duration of these patients was three to eighty eight months(median twenty two months) and the overall five-year survival and event free survival rate were 62.1% and 57.5%, respectively.
CONCLUSION
These data demonstrate that intraarterial cisplatin can be used as an effective regimen preoperatively for pediatric patients with extremity osteosarcoma. The combined use of systemic doxorubicin is expected to improve survival in patients with pulmonary metastasis.

Keyword

Osteosarcoma; Intraarterial cisplatin; Survival rate

MeSH Terms

Amputation
Chemotherapy, Adjuvant
Cisplatin*
Diagnosis
Disease-Free Survival
Doxorubicin
Drug Therapy
Extremities
Follow-Up Studies
Humans
Limb Salvage
Neoplasm Metastasis
Osteosarcoma*
Recurrence
Seoul
Survival Rate
Cisplatin
Doxorubicin
Full Text Links
  • JKCA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr